| Title |
Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic
|
|---|---|
| Published in |
Infectious Diseases and Therapy, June 2022
|
| DOI | 10.1007/s40121-022-00667-z |
| Pubmed ID | |
| Authors |
E. Ariza-Vioque, F. Ello, H. Andriamamonjisoa, V. Machault, J. González-Martín, M. C. Calvo-Cortés, S. Eholié, G. A. Tchabert, T. Ouassa, M. Raberahona, R. Rakotoarivelo, H. Razafindrakoto, L. Rahajamanana, R. J. Wilkinson, A. Davis, M. Maxebengula, F. Abrahams, C. Muzoora, N. Nakigozi, D. Nyehangane, D. Nanjebe, H. Mbega, R. Kaitano, M. Bonnet, P. Debeaudrap, J. M. Miró, X. Anglaret, N. Rakotosamimanana, A. Calmy, F. Bonnet, J. Ambrosioni |
| Abstract |
Tuberculous meningitis (TBM) is the most severe and disabling form of tuberculosis (TB), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals co-infected with human immunodeficiency virus type 1 (HIV-1). To evaluate the efficacy and safety of an intensified anti-tubercular regimen and an anti-inflammatory treatment, the INTENSE-TBM project includes a phase III randomised clinical trial (TBM-RCT) in four countries in sub-Saharan Africa (SSA). Within this framework, we designed a comprehensive capacity-building work package ensuring all centres had, or would acquire, the ability to conduct the TBM-RCT and developing a network of skilled researchers, clinical centres and microbiology laboratories. Here, we describe these activities, identify strengths/challenges and share tools adaptable to other projects, particularly in low- and lower-middle income countries with heterogeneous settings and during the coronavirus disease 2019 (COVID-19) pandemic. Despite major challenges, TBM-RCT initiation was achieved in all sites, promoting enhanced local healthcare systems and encouraging further clinical research in SSA. In terms of certified trainings, the achievement levels were 95% (124/131) for good clinical practice, 91% (39/43) for good clinical laboratory practice and 91% (48/53) for infection prevention and control. Platform-based research, developed as part of capacity-building activities for specific projects, may be a valuable tool in fighting future infectious diseases and in developing high-level research in Africa. |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 19% |
| Madagascar | 1 | 6% |
| France | 1 | 6% |
| Chile | 1 | 6% |
| United Kingdom | 1 | 6% |
| Netherlands | 1 | 6% |
| Unknown | 8 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 69% |
| Practitioners (doctors, other healthcare professionals) | 4 | 25% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 78 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 9% |
| Student > Bachelor | 6 | 8% |
| Lecturer | 5 | 6% |
| Researcher | 4 | 5% |
| Student > Postgraduate | 3 | 4% |
| Other | 6 | 8% |
| Unknown | 47 | 60% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Medicine and Dentistry | 5 | 6% |
| Environmental Science | 4 | 5% |
| Nursing and Health Professions | 3 | 4% |
| Immunology and Microbiology | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 49 | 63% |